Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Diabetes Treatment and Management, and Cardiac pacing and defibrillation studies.
Identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease: a multidisciplinary consensus and modified Delphi study
Finerenone and Atrial Fibrillation in Heart Failure
The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology
iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025
The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology
Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
Global Variations in Heart Failure Etiology, Management, and Outcomes
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Management of Worsening Heart Failure With Reduced Ejection Fraction
The HFSA Advanced Heart Failure and Transplant Cardiology Fellowship Consensus Conference
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
Automated E-Counseling for Chronic Heart Failure
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure